NCT01703949
Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 37 versions: 27 with changes below, 10 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria shortened, about 17 words
- Study completion moved earlier from Jun 3, 2030 to Aug 16, 2028
- Site details revised
- Notable Results first posted: May 12, 2026
- Primary endpoint revised
- Minor Primary completion date changed from estimate of Apr 21, 2025 to Jun 3, 2025
- Study completion date: Apr 21, 2030 to Jun 3, 2030
Minor Trial status: Recruiting to Active, Not Recruitingv34 Show 4 more changesShow less
- Enrollment target: estimated 40 to confirmed 28
- Primary completion date: Mar 1, 2025 to Apr 21, 2025
- Study completion date: Mar 1, 2026 to Apr 21, 2030
- Site details revised
- Notable Primary completion date: Sep 1, 2024 to Mar 1, 2025
- Study completion date: Sep 1, 2025 to Mar 1, 2026
Show 21 earlier versionsHide 21 earlier versions
- Notable Eligibility criteria expanded, about 11 wordsv29
- Notable Primary completion date: Jan 15, 2024 to Sep 1, 2024
- Study completion date: Jan 15, 2024 to Sep 1, 2025
- Notable Eligibility criteria expanded, about 16 wordsv26
- Notable Primary and study completion dates: Jan 15, 2023 to Jan 15, 2024v25
- Minor Collaborators shortened, about 4 wordsv24
- Notable Primary and study completion dates: Jan 15, 2022 to Jan 15, 2023
- Study description shortened, about 192 words
- Site contact updated
- Notable Primary and study completion dates: Jan 15, 2021 to Jan 15, 2022v21
- Minor Study completion date: Jan 15, 2021v20
- Minor Eligibility criteria revised
- Site contact updated
- Study description shortened, about 2 words
Notable Phase: Not applicable to Phase 2v17 Show 8 more changesShow less
- Trial status: Active, Not Recruiting to Recruiting
- Enrollment target: 8 to 40
- Eligibility criteria expanded, about 170 words
- Interventions: Brentuximab Vedotin (Drug), Laboratory Biomarker Analysis (Other) to Brentuximab Vedotin (Drug), Laboratory Biomarker Analysis (Other), Nivolumab (Biological)
- Study description expanded, about 98 words
- Site details revised
- Study arms: 1 to 2
- Study title expanded, about 4 words
- Notable Primary completion date: Jun 2015 to Jan 15, 2021
- Start date: Mar 2013 to Mar 20, 2013
- Minor Interventions: brentuximab vedotin (Drug), laboratory biomarker analysis (Other) to Brentuximab Vedotin (Drug), Laboratory Biomarker Analysis (Other)
- Study site revised
- Study description expanded, about 1 word
- Minor Primary completion date changed from estimate of Dec 2016 to Jun 2015v13
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 20 to confirmed 8
- Site details revised
- Minor Primary completion date: Jun 2016 to Dec 2016v11
- Notable Primary completion date: Jun 2015 to Jun 2016v10
- Minor Primary completion date: Mar 2015 to Jun 2015v9
- Study Identification, Study Status, Study Description, Arms and Interventionsv6
- Notable Lead sponsor: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium to University of Washingtonv5
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Apr 2013 to Mar 2013
- Site details revised
- Notable Start date: Oct 2012 to Apr 2013v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Overall Response Rate as Measured by the Cheson 2007 Criteria
Timeframe: For Arm A: Up to 5 weeks after completion of study treatment (an average of 1 month). For Arm B: within 6 months following treatment (an average of 1 month).
Arms and interventions
Arm A (brentuximab vedotin)Experimental
Patients receive brentuximab vedotin IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
Arm B (brentuximab vedotin, nivolumab)Experimental
Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
Drugs: Brentuximab Vedotin
Other: Laboratory Biomarker Analysis
Biologicals: Nivolumab
Sites
1 site in 1 country
- Fred Hutch/University of Washington Cancer ConsortiumSeattle, Washington, United States